Drug Profile
Research programme: biosimilars - Amphastar Pharmaceuticals
Latest Information Update: 28 Dec 2022
Price :
$50
*
At a glance
- Originator Amphastar Pharmaceuticals
- Class Biological factors
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 28 Dec 2022 No recent reports of development identified for preclinical development in Unspecified in USA
- 29 Dec 2020 Preclinical development is ongoing in Undefined indication in USA
- 08 Nov 2016 Preclinical trials in Undefined indication in USA before November 2016